What's in the Pipeline? Drugs in Development for Autism Spectrum Disorder

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2014 Mar 5

PMID 24591832

Citations 6

Authors

Min Sung

Chee Hon Chin

Choon Guan Lim

Hwee Sen Alvin Liew

Chau Sian Lim

Esperance Kashala

Shih-Jen Weng

Affiliations

Soon will be listed here.

Abstract

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental disorder with both core symptoms and associated symptoms (eg, irritability, aggression, and comorbidities) that affect both the individual and the family/systems around them. There have been recent advances in the understanding of the underlying pathophysiology of ASD pertaining to genetics, epigenetics, neurological, hormonal, and environmental factors that contribute to the difficulties found in individuals with ASD. With this improved understanding, there has been a shift in the application of psychopharmacology in ASD and its related disorders. A literature review was conducted to examine research published in the last 5 years between different classes of psychotropic medications and ASD. The broad scope of the existing literature for the use of conventional medications is summarized and novel medications are discussed.

Citing Articles

Exploratory analysis of L1 retrotransposons expression in autism.

Spirito G, Filosi M, Domenici E, Mangoni D, Gustincich S, Sanges R Mol Autism. 2023; 14(1):22.

PMID: 37381037 PMC: 10303858. DOI: 10.1186/s13229-023-00554-5.

Molecular Mechanisms of Aberrant Neuroplasticity in Autism Spectrum Disorders (Review).

Anashkina A, Erlykina E Sovrem Tekhnologii Med. 2021; 13(1):78-91.

PMID: 34513070 PMC: 8353687. DOI: 10.17691/stm2021.13.1.10.

Practitioner's review: medication for children and adolescents with autism spectrum disorder (ASD) and comorbid conditions.

Popow C, Ohmann S, Plener P Neuropsychiatr. 2021; 35(3):113-134.

PMID: 34160787 PMC: 8429404. DOI: 10.1007/s40211-021-00395-9.

Mutations From Whole Exome Sequencing in Neurodevelopmental and Psychiatric Disorders: From Discovery to Application.

Wang W, Corominas R, Lin G Front Genet. 2019; 10:258.

PMID: 31001316 PMC: 6456656. DOI: 10.3389/fgene.2019.00258.

Gonadotropin-releasing hormone agonist against severe aggression in autism.

van der Weiden R, Helmerhorst F, Eriksson T BMJ Case Rep. 2016; 2016.

PMID: 27655876 PMC: 5051425. DOI: 10.1136/bcr-2016-216378.

References

Davis N, Kollins S . Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics. 2012; 9(3):518-30. PMC: 3441928. DOI: 10.1007/s13311-012-0126-9. View

Stigler K, Diener J, Kohn A, Li L, Erickson C, Posey D . Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol. 2009; 19(3):265-74. PMC: 2872206. DOI: 10.1089/cap.2008.093. View

Hollander E, Wasserman S, Swanson E, Chaplin W, Schapiro M, Zagursky K . A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006; 16(5):541-8. DOI: 10.1089/cap.2006.16.541. View

Lambrey S, Falissard B, Martin-Barrero M, Bonnefoy C, Quilici G, Rosier A . Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder. J Child Adolesc Psychopharmacol. 2010; 20(1):79-80. DOI: 10.1089/cap.2009.0057. View

Scahill L, Aman M, McDougle C, McCracken J, Tierney E, Dziura J . A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006; 16(5):589-98. DOI: 10.1089/cap.2006.16.589. View

Jesner O, Aref-Adib M, Coren E . Risperidone for autism spectrum disorder. Cochrane Database Syst Rev. 2007; (1):CD005040. PMC: 9022437. DOI: 10.1002/14651858.CD005040.pub2. View

Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D . Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012; 21(6):700-9. DOI: 10.1111/j.1365-2869.2012.01021.x. View

Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J . Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2009; 35(4):990-8. PMC: 2846602. DOI: 10.1038/npp.2009.202. View

Ching H, Pringsheim T . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012; (5):CD009043. DOI: 10.1002/14651858.CD009043.pub2. View

10.

Andari E, Duhamel J, Zalla T, Herbrecht E, Leboyer M, Sirigu A . Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A. 2010; 107(9):4389-94. PMC: 2840168. DOI: 10.1073/pnas.0910249107. View

11.

Shimmura C, Suda S, Tsuchiya K, Hashimoto K, Ohno K, Matsuzaki H . Alteration of plasma glutamate and glutamine levels in children with high-functioning autism. PLoS One. 2011; 6(10):e25340. PMC: 3187770. DOI: 10.1371/journal.pone.0025340. View

12.

Williams K, Wheeler D, Silove N, Hazell P . Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010; (8):CD004677. DOI: 10.1002/14651858.CD004677.pub2. View

13.

Malow B, Adkins K, McGrew S, Wang L, Goldman S, Fawkes D . Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2011; 42(8):1729-37. PMC: 3368078. DOI: 10.1007/s10803-011-1418-3. View

14.

Potenza M, Holmes J, Kanes S, McDougle C . Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999; 19(1):37-44. DOI: 10.1097/00004714-199902000-00008. View

15.

Green J, Hollander E . Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics. 2010; 7(3):250-7. PMC: 5084228. DOI: 10.1016/j.nurt.2010.05.006. View

16.

Posey D, Puntney J, Sasher T, Kem D, McDougle C . Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol. 2004; 14(2):233-41. DOI: 10.1089/1044546041649084. View

17.

Kent J, Kushner S, Ning X, Karcher K, Ness S, Aman M . Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord. 2012; 43(8):1773-83. DOI: 10.1007/s10803-012-1723-5. View

18.

Burket J, Herndon A, Winebarger E, Jacome L, Deutsch S . Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: possible implications for the pharmacotherapy of autism spectrum disorders. Brain Res Bull. 2011; 86(3-4):152-8. DOI: 10.1016/j.brainresbull.2011.08.001. View

19.

Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S . Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012; 3(1):16. PMC: 3539865. DOI: 10.1186/2040-2392-3-16. View

20.

Rezaei V, Mohammadi M, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh S . Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34(7):1269-72. DOI: 10.1016/j.pnpbp.2010.07.005. View